Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.56 |
| ▸ | APOB | P04114 | 9/20 | 0.54 |
| ▸ | MTTP | P55157 | 8/20 | 0.54 |
| ▸ | LMNA | P02545 | 5/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 6/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.51 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6794883 | 0.89 | P2RX1 (0.56) | P2RX1APOBMTTPLMNAMAPT | |
| SCHEMBL6638787 | 0.88 | LMNA (0.55) | TP53P2RX1LMNAMEN1KMT2A | |
| SCHEMBL6488558 | 0.87 | LMNA (0.50) | TP53P2RX1APOBMTTPLMNA | |
| SCHEMBL6789872 | 0.87 | TP53 (0.53) | TP53P2RX1LMNAMEN1KMT2A | |
| SCHEMBL6805325 | 0.83 | KCNMA1 (0.51) | P2RX1APOBMTTPLMNAMEN1 | |
| SCHEMBL6805317 | 0.83 | KCNMA1 (0.51) | P2RX1APOBMTTPLMNAMEN1 | |
| SCHEMBL6794433 | 0.83 | ABCG2 (0.70) | P2RX1APOBMTTPMEN1KMT2A | |
| SCHEMBL1455315 | 0.80 | MAPT (0.77) | TP53LMNAMEN1KMT2AHTT | |
| SCHEMBL6804166 | 0.79 | SMO (0.61) | P2RX1APOBMTTPLMNAHTT | |
| SCHEMBL14031525 | 0.79 | KCNMA1 (0.66) | P2RX1APOBMTTPLMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040157866-A1 | Amide compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-08-12 | — | — | US | disclosed |
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | APOB, APOL1, SCARB1 | TP53 4865/4885P2RX1 3450/4885APOB 1/4885 |
| US-20040157866-A1 | Amide compounds | APOB, NR1H2, NR1H3 | TP53 4791/4885P2RX1 4122/4885APOB 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.